Literature DB >> 9274725

Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression.

A I Michou1, L Santoro, M Christ, V Julliard, A Pavirani, M Mehtali.   

Abstract

E1-deleted adenovirus (Ad) vectors expressing the human coagulation factor IX (hFIX) or the bacterial beta-galactosidase (lacZ) were injected intravenously into various strains of immunocompetent (C57BI/6, BALB/c, CD1, CBA/J, C3H) and immunodeficient (BALB/c-nu/nu, C57BI/6-nu/nu, SCID, NIH-bg-nu-xid) mice. Regular analysis of mouse sera and tissues showed a persistent expression of both transgenes in immunodeficient mice, while detection diminished very rapidly in immunocompetent mice. The mechanisms responsible for the transient detection of the two transgenes were however not identical. Rapid decline of lacZ expression was correlated with a rapid decrease of viral DNA sequences, and consequently to the induction of a cellular immune response to the lacZ antigen. In contrast, absence of detectable levels of serum hFIX in immunocompetent animals was not associated with a loss of viral DNA but was strictly correlated with the induction of anti-hFIX antibodies. Surprisingly, anti-hFIX antibodies were never detected in C57BI/6 mice, leading to prolonged detection of hFIX. These results suggest that cellular immunity to viral antigens plays a minor role in the early extinction of transgene expression and illustrate the influence of the cellular (eg lacZ) or humoral (eg hFIX) immunity to transgene-encoded products on the persistence of transgene expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9274725     DOI: 10.1038/sj.gt.3300412

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  33 in total

1.  Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

Authors:  D B Schowalter; C L Himeda; B L Winther; C B Wilson; M A Kay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

3.  Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Authors:  Zachary C Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

4.  Genetic heterogeneity and efficiency of two different methods of adenovirus-mediated gene transfer in a rat liver transplantation model.

Authors:  Kensuke Adachi; Masayuki Fujino; Yusuke Kitazawa; Naoko Funeshima; Xiao-Kang Li
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

5.  Adenovirus serotype 5 L4-22K and L4-33K proteins have distinct functions in regulating late gene expression.

Authors:  Susan J Morris; Keith N Leppard
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 6.  Targeting the central nervous system with herpes simplex virus / Sleeping Beauty hybrid amplicon vectors.

Authors:  Suresh de Silva; William J Bowers
Journal:  Curr Gene Ther       Date:  2011-10       Impact factor: 4.391

Review 7.  Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage.

Authors:  Gavin Thurston
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

8.  A simple technique to establish a long-term adenovirus mediated gene transfer to the heart of newborn mice.

Authors:  Marina Jerebtsova; Xuehai Ye; Patricio E Ray
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2009-06

9.  Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.

Authors:  Zachary C Hartman; Daniel M Appledorn; Delila Serra; Oliver Glass; Todd B Mendelson; Timothy M Clay; Andrea Amalfitano
Journal:  Virology       Date:  2008-02-15       Impact factor: 3.616

10.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.